Dallas-based Meros Investment Management purchased 159,945 shares of Azenta valued at $4.6 million in the third quarter, representing 2% of their 13F reportable assets under management. This marked a new position for Meros, not held in the prior period. Shares of Azenta were priced at $35.05, down 22% over the past year.

An SEC filing on November 14 revealed that Meros Investment Management acquired 159,945 shares of Azenta, totaling $4.6 million in the third quarter. This new position represented 2% of the fund’s $234.2 million in reportable U.S. equity holdings. Azenta is involved in automated cold sample management systems for the life sciences sector.

Azenta provides automated cold sample management systems, sample preparation equipment, and laboratory services for the life sciences industry. They generate revenue through product sales and service contracts, serving pharmaceutical companies, biorepositories, and research institutes globally. The company’s improving fundamentals and expected margin expansion make it a strategic partner for scientific discovery and innovation.

For long-term investors, Azenta’s improving fundamentals and expected margin expansion make it a stock worth watching. The company recently reported a 4% revenue growth and a 310-basis-point rise in adjusted EBITDA margin. With $546 million in cash and improving free cash flow, Azenta is poised for growth in the next fiscal year. The $4.6 million stake represents 2% of the fund’s U.S. equity book.

Azenta, Inc. is a leading provider of sample management and laboratory solutions for the global life sciences industry. The company leverages advanced automation and integrated service offerings to support research, drug development, and biobanking initiatives. Its diversified customer base and end-to-end solutions position it as a strategic partner for organizations focused on scientific discovery and innovation.

Read more at Yahoo Finance: Why a $5 Million Bet on Azenta Could Pay Off After a 70% Stock Slide